CureVac
CVAC
CVAC was delisted on the 5th of January, 2026.
88 hedge funds and large institutions have $114M invested in CureVac in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 32 reducing their positions, and 38 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.26% less ownership
Funds ownership: 7.73% → 4.47% (-3.3%)
13% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 32
21% less funds holding
Funds holding: 111 → 88 (-23)
28% less call options, than puts
Call options by funds: $9.43M | Put options by funds: $13.1M
58% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 38
60% less capital invested
Capital invested by funds: $283M → $114M (-$169M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$6.35M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$2.65M |
| 3 |
Morgan Stanley
New York
|
+$2.58M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
+$2.18M |
| 5 |
JP Morgan Chase
New York
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$60M |
| 2 |
BlackRock
New York
|
-$14.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.84M |
| 4 |
State Street
Boston,
Massachusetts
|
-$8.77M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$4.65M |
CVAC Hedge Fund Activity: Q2 2022 in Review
88 of the 5,957 institutional investors tracked by Wall St. Rank reported a position in CureVac (CVAC) for Q2 2022, worth a combined $114M — down 60% from $283M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of CVAC and 16 opened new positions — a net loss of 22 holders — while 32 trimmed existing stakes and 28 added.
The largest buyer was Goldman Sachs, adding an estimated $6.35M. The largest seller was Baillie Gifford & Co, cutting an estimated $60M.
- 88 institutional investors held CureVac (CVAC) as of Q2 2022, down from 111 in Q1 2022.
- Funds reported $114M of CureVac stock for Q2 2022, down 60% quarter-over-quarter.
- 16 funds opened new CureVac positions in Q2 2022 and 38 closed out, a net change of -22 holders.
- The largest CureVac buyer in Q2 2022 was Goldman Sachs, an estimated $6.35M added.
- The largest CureVac seller in Q2 2022 was Baillie Gifford & Co, an estimated $60M sold.
Based on aggregated 13F filings for Q2 2022.